BiotechTube
Peptinovo Biopharma

Peptinovo Biopharma

San Diego, United States· Est.
peptinovo.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Peptinovo Biopharma is a private, pre-revenue biotech developing a novel nanoparticle drug delivery platform called PALM™ to reformulate and improve existing chemotherapies. The company's initial pipeline targets a broad range of solid tumors, with its lead asset, PNB-281 (paclitaxel), in late preclinical testing and aiming for an IND filing and first-in-human trials by late 2024. Founded in 2018 by seasoned industry veterans, the company leverages deep expertise in drug development to advance a platform that could significantly enhance the therapeutic index of multiple oncology drugs.

Oncology

Technology Platform

PALM™ (Peptide-Assisted Lipid Micelle) smart drug delivery platform; a nanoparticle carrier designed to improve efficacy and reduce side effects of chemotherapy drugs for solid tumors.

Opportunities

The platform offers a capital-efficient strategy to create improved, high-value versions of established chemotherapy drugs with known multi-billion dollar markets.
Success with the lead asset could validate the PALM™ technology, enabling rapid expansion into a broad pipeline and attracting lucrative partnership or acquisition interest from large oncology-focused pharmaceutical companies.

Risk Factors

High risk that preclinical results fail to translate into clinical safety and efficacy, which is common in drug delivery.
The company faces significant financing risk as a private, pre-revenue entity needing to fund costly clinical trials.
It also operates in a highly competitive landscape against generic chemotherapies and other advanced formulations.

Competitive Landscape

Peptinovo competes in the crowded oncology drug delivery and reformulation space, which includes companies developing liposomal, nanoparticle, antibody-drug conjugate (ADC), and polymer-based technologies. Key competitors range from large pharma with approved products (e.g., Abraxane, liposomal doxorubicin) to numerous biotech startups. Differentiation will require demonstrating superior clinical benefit.

More companies in Drug Delivery & Formulation →More companies in United States →